Krebs Biochemicals & Industries Ltd. - Research Center
524518 KREBSBIO Group (B) BSE data
Results
Statement
More
Mar ' 23 |
Mar ' 22 |
Mar ' 21 |
Mar ' 20 |
Mar ' 19 |
Equity share capital
21.56 |
21.56 |
19.62 |
18.00 |
16.63 |
Share application money
Preference share capital
Reserves & surplus
-121.02 |
-96.65 |
-66.52 |
-50.65 |
-30.92 |
Secured loans
53.24 |
12.92 |
100.55 |
65.51 |
- |
Unsecured loans
Total
83.77 |
67.82 |
57.81 |
40.51 |
35.94 |
Gross block
301.06 |
286.16 |
259.72 |
242.22 |
233.78 |
Less : revaluation reserve
Less : accumulated depreciation
153.75 |
147.45 |
141.79 |
136.93 |
132.51 |
Net block
147.31 |
138.71 |
117.93 |
105.29 |
101.27 |
Capital work-in-progress
4.09 |
8.38 |
11.94 |
4.19 |
3.48 |
Investments
Current assets, loans & advances
23.58 |
42.72 |
29.36 |
24.32 |
37.62 |
Less : current liabilities & provisions
91.21 |
121.98 |
101.41 |
93.29 |
106.43 |
Total net current assets
-67.62 |
-79.26 |
-72.05 |
-68.97 |
-68.81 |
Miscellaneous expenses not written
Total
83.77 |
67.82 |
57.81 |
40.51 |
35.94 |
Book value of unquoted investments
Market value of quoted investments
Contingent liabilities
Number of equity sharesoutstanding (Lacs)
215.60 |
215.60 |
196.20 |
180.00 |
166.30 |